Peptide program margin is decided before your first order ships. Six choices govern it: sourcing lane, pharmacy spread, consult pricing, refill cadence, support load, and churn. This teardown models each with sourced inputs, then shows which two actually move the number.
Peptide program margin dies in month four. Not at launch, when the ad spend is fresh and the first cohort converts. Month four, when reorder volume is supposed to compound, it instead flattens, and the operator discovers that everything profitable about the business was sitting in refills that never came.
You have probably read the peptide market analyses. Peptide therapeutics were valued at $140.9 billion in 20230-day5 and are projected at $164.0 billion for 2026, growing at 8.7% a year through 2033 (1). Useful for a board deck. Useless on a Tuesday when you are deciding whether to sign a 90-day fill schedule or a 30 day one.
So this is the other document. Not the peptide market, the operator P&L: what each line costs, which decision controls it, and where the margin actually leaks. Every input below is sourced and every model is labelled as a model. No customer names, no invented client, no rounding in our favor.
The line items nobody publishes
Here is a modelled per member, per month view of a cash pay program at roughly 1,000 active members. It follows the same contribution logic we use when breaking down peptide business margins across compounds. The ranges are wide on purpose. The width is the point: each spread is a decision you have already made or are about to.
Modelled contribution margin, per active member per month. Illustrative, not a quote.
| Line | Per member / month | Where the input comes from |
|---|---|---|
| Program fee collected | $149 | Published telehealth membership rate, medication billed separately (2) |
| Medication margin retained | $0 to $45 | Pass through versus a negotiated dispensing arrangement |
| Clinical review | ($14) to ($32) | Intake evaluation plus per refill provider attestation |
| Pharmacy coordination and shipping | ($9) to ($19) | Cold chain, signature delivery, reship rate |
| Payment processing | ($6) to ($11) | 3.5% to 7% effective cost on high risk merchant categories (3) |
| Member support | ($7) to ($16) | 0.6 to 1.2 contacts per member month at loaded agent cost |
| Platform, licensing and audit trail | ($11) to ($24) | Multi state provider coverage, records retention, monitoring |
| Contribution margin | $50 to $102 | 34% to 68% of program fee |
A 34-point swing on identical revenue. That gap is the whole business, and it is closed by six decisions.
| Rank and decision | Effect | Why it ranks here |
|---|---|---|
| 01 Retention past month three | Sets tenure | Multiplies every other line below it |
| 02 Sourcing lane | $30 swing | Legally constrained, slow to change |
| 03 Consult pricing model | $18 swing | Fastest to restructure |
| 04 Refill cadence | $15 swing | Trades cost against dispute exposure |
| 05 Pharmacy spread | $15 swing | Contract bound, compliance conditioned |
| 06 Support load | $9 swing | Driven by interface, not headcount |
Ranked by effect on lifetime contribution, not by monthly dollars. Number one multiplies the other five.
Decision 1: Which sourcing lane you are actually in
This is a legal question that presents as a procurement question, and it sets the ceiling on everything below it.
The FDA resolved the tirzepatide shortage on 19 December 2024 and the semaglutide shortage on 21 February 2025, with compounding enforcement discretion ending 18 February and 22 April 2025 for 503A pharmacies, and 19 March and 22 May 2025 for 503B outsourcing facilities (4). On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list entirely, finding no clinical need for outsourcing facilities to compound them from bulk substances. Comments closed 29 June 2026 (5). Separately, the interim 503A bulks list places substances with significant identified safety concerns in Category 2, where the agency has said it would consider enforcement action against compounders using them (6).
The 503A vs 503B question sits upstream of every number in the table above, because it decides which costs are even yours to negotiate.
Read as an operator: bulk compounded supply is not a cost lane you can underwrite a three-year model against. Branded cash pay is. Novo Nordisk cut self-pay pricing to $349 a month for Wegovy and most Ozempic doses in November 2025, distributed through direct pharmacy, retail, and telehealth partners (7). Thinner per unit, far more durable.
The operators who survived 2025 were not the ones with the cheapest vial. They were the ones whose peptide program cost structure did not assume a single lane would stay open.
Decision 2: Who keeps the pharmacy spread
Three positions, and most operators pick one by accident.
Pure pass through. The member pays the pharmacy, you take zero product margin and zero product risk. Clean, defensible, and it caps your peptide business revenue at the program fee.
Negotiated dispensing arrangement. You hold a fee for service relationship with the fulfillment partner, and the terms you get depend heavily on how you ran the white label pharmacy evaluation before signing. Modelled at $0 to $45 per member month, this is the single largest movable line in the table, and the one with the most compliance conditions attached to how it is structured and disclosed.
Owning fulfillment. Inventory risk, cold chain, licensure by state. Real margin, real capital, and a fixed cost base that only works above volumes most operators will not reach in year one.
Decision 3: How you price clinical review
Per-visit pricing looks cheapest on a spreadsheet and is the most expensive in practice, because it charges you again every time a dose changes. Bundling review into the program fee smooths the cost but hides it, and the hidden version is the one that surprises you at 2,000 members.
Two structural variables move this line more than the rate itself: whether refill authorization runs through an asynchronous telehealth workflow against a structured record or requires a scheduled visit, and how many states your provider network is licensed in. A program operating in eight states and a program operating in forty eight have very different clinical review costs at the same volume, and almost identical peptide program pricing on the front end.
Decision 4: Refill cadence, the lever that cuts both ways
Moving from 30-day to 90 day fills removes two-thirds of your shipping events, two-thirds of your coordination overhead, and two-thirds of your card authorizations. On the modelled numbers, that is roughly $15 per member month, and it is the clearest illustration of how subscription refills drive the economics of the whole channel.
It also concentrates risk. A member who stops in week five of a 90-day fill is a refund conversation or a chargeback, and chargebacks on high-risk merchant categories run $15 to $35 per dispute before the processor reconsiders your reserve (3). Longer cadence collects more cash sooner and converts churn into disputes. Shorter cadence collects less and lets churn exit quietly.
There is no correct answer. There is only a cadence matched to your actual month three retention, which brings us to the decision that governs the rest.
Decision 5: Support load is a product decision
Every operator budgets support as a headcount line and then watches it behave like a product line. Contacts per member month are driven by things decided months earlier: how clearly dosing steps are communicated in the storefront, whether shipment status is visible without a ticket, whether a member can see their own next fill date.
The modelled range runs $7 to $16 per member month. At 5,000 members, that is a $540,000 annual difference produced entirely by interface decisions, not by staffing ones.
Decision 6: Churn, which multiplies everything above
Here is the number that should govern your model. In a study of 5,780 commercially insured adults without diabetes who started GLP-1 therapy between January 2021 and March 2022, persistence at three years was 8.1%, roughly one in twelve (8). One year persistence in more recent cohorts improved substantially, reaching 62.6% for obesity indicated products among 2024 initiators as supply stabilized (8). Both figures are real. The spread between them is your planning risk.
Run it: at $76 contribution per member month, a seven-month median tenure returns $532 of lifetime contribution. At three months it returns $228. That is your acquisition ceiling, and it is not a marketing number; it is an arithmetic one.
Which is why peptide program margin is a retention problem wearing a procurement costume. You can win $45 on sourcing and lose $300 on tenure in the same quarter.
What fails, and it is rarely the model
On 3 March 2026 the FDA issued 30 warning letters to telehealth organizations over compounded GLP-1 marketing. The two violations cited were claims that compounded versions were identical to FDA approved products, and advertising medications under the firm's own brand without clarifying that the firm was not the compounder (9).
Both are storefront decisions. Neither appears anywhere in a financial model. Both can close a revenue channel faster than any cost line can drain it. This is the argument for keeping the commercial layer and the clinical layer structurally separate rather than blended: the operator runs the storefront, brand, and member experience, while licensed clinical review and pharmacy fulfillment run behind it in a defined workflow with its own records, its own attestations, and its own audit trail.
Where the infrastructure decision fits
FUSE Health exists because six decisions this consequential should not be rebuilt from scratch by every operator entering the peptide market. We supply the healthcare storefront infrastructure: the commerce layer operators control, connected to licensed provider workflows, pharmacy fulfillment, payment handling built for this merchant category, and the records trail that makes each of the above defensible when volume scales or a regulator asks.
Operators sell programs. The clinical and fulfillment machinery runs behind the storefront in a structured workflow, not an improvised one. That separation is what keeps a peptide program cost structure legible at 500 members and still legible at 15,000.
The decision you are actually making
You are not choosing a vendor. You are choosing which of these six decisions you will own and which you will inherit from whoever you build on.
Inherit the wrong sourcing lane and a regulatory date resets your cost base. Inherit the wrong consult structure and every dose adjustment bills you twice. Inherit a payments setup not built for this category, and a reserve hold arrives in the quarter you can least afford it. None of that shows up in a peptide market forecast, and all of it shows up in month four.
Build the storefront you control on infrastructure that has already absorbed those decisions, and the margin question becomes the only one worth arguing about: how long members stay.
Regulatory and editorial note
This article is written for business operators and covers commercial structure only. It contains no medical guidance, no dosing information, and no treatment recommendations, and it is not a substitute for legal, regulatory, or clinical advice. Compounding rules, bulk list status, and enforcement posture change; verify current FDA guidance and applicable state pharmacy and telehealth law with qualified counsel before making sourcing or program decisions. All financial figures are modelled ranges built from the publicly sourced inputs cited above and are illustrative only. They are not a quote, a projection, or a representation of any FUSE Health customer's results.
References
- Peptide Therapeutics Market Size & Share Report, 2026 to 2033, Grand View Research
- Weight Loss FAQs, Hims
- High-Risk Merchant Account Fees: Complete Guide for 2026, TailoredPay
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S. Food and Drug Administration
- FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs, Orrick, May 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, U.S. Food and Drug Administration
- Novo unveils newly reduced self-pay prices for Wegovy, Ozempic, Fierce Pharma, November 2025
- GLP-1 Therapy to Treat Obesity Among Members Without Diabetes: Three-Year Persistence, Prime Therapeutics
- Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s, Pharmaceutical Technology, March 2026
Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.
- Background
- Startup Operations & Service Systems
- Experience
- 2x Founder, Multi-Market U.S. Scaling
- Qualifications
- Healthtech Market Expertise & Operational Scaling
- Key Achievement
- Scaled Premier Staff & Eventstaff across major U.S. markets
